Mémin E, Genzale M, Crow M, Molina CA (2011) Evidence that phosphorylation by the mitotic kinase Cdk1 promotes ICER monoubiquitination and nuclear delocalization. Exp Cell Res 317, 2490-502 21767532

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S271-p - CREM (human) ▲

Modsite: QGVVMAAsPGsLHsP SwissProt Entrez-Gene Orthologous residues CREM (human): S271‑p, CREM iso2 (human): S163‑p, CREM iso6 (human): S275‑p, CREM iso8 (human): S47‑p, CREM (mouse): S284‑p, CREM iso2 (mouse): S172‑p, CREM iso3 (mouse): S172‑p, CREM (rat): S284‑p Characterization Methods used to characterize site in vivo:  mass spectrometry (in vitro), mutation of modification site, phosphoamino acid analysis Disease tissue studied:  prostate cancer Relevant cell lines - cell types - tissues:  HeLa (cervical), LNCaP (prostate cell) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE CDK1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CDK1 (human) co-immunoprecipitation, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes seliciclib decrease Downstream Regulation Effect of modification (function):  intracellular localization, ubiquitination Effect of modification (process):  transcription, induced

S277-p - CREM (human) ▲

Modsite: AsPGsLHsPQQLAEE SwissProt Entrez-Gene Orthologous residues CREM (human): S277‑p, CREM iso2 (human): S169‑p, CREM iso6 (human): S281‑p, CREM iso8 (human): S53‑p, CREM (mouse): S290‑p, CREM iso2 (mouse): S178‑p, CREM iso3 (mouse): S178‑p, CREM (rat): S290‑p Characterization Methods used to characterize site in vivo:  mass spectrometry (in vitro), mutation of modification site, phosphoamino acid analysis Relevant cell lines - cell types - tissues:  HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE CDK1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CDK1 (human) co-immunoprecipitation, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes seliciclib decrease